Reliable pharmaceutical market forecasting requires moving beyond a simple reading of the FDA Orange Book. Investors and analysts frequently treat […]
A deep-dive into the economics, IP strategy, and competitive dynamics shaping two divergent paths for branded generic pharmaceutical companies The
Two Roads to Generic Drug Profits: The US Niche Strategy vs. India’s Mass Market Model Read Post »
The pharmaceutical industry operates on a model where the expiration of a primary patent is no longer the end of
The Cliff Is Real, and the Numbers Are Getting Worse The pharmaceutical revenue cliff is not a metaphor. It is
The pharmaceutical industry spent roughly $2.3 billion and 12 years, on average, bringing a single new molecular entity to market
Every year, pharmaceutical companies abandon thousands of patents. They miss maintenance fee deadlines. They fail to validate patents in markets
Patent Gaps Pay: The Regional Launch Windows Hidden Inside Abandoned Drug Patents Read Post »
What FTO Actually Means (And What It Doesn’t) The Legal Definition and Its Limits Freedom-to-operate analysis is one of the
De-Risk Your Pipeline: The Definitive Guide to Freedom-to-Operate Analysis in Biopharma Read Post »
Humira, AbbVie’s blockbuster arthritis drug, generated more than $200 billion in cumulative revenue before biosimilar competitors could reach American patients
How Drug Companies Turn 20-Year Patents Into 40-Year Monopolies Read Post »
The Problem With Citation Counts A patent that has been cited 400 times sounds impressive. An IP manager can drop
Sign in or create a free account to read this DrugPatentWatch article
